ERAS
Kaplan Fox Encourages Investors of Erasca, Inc. (ERAS) Who Suffered Losses to Contact the Firm Before August 10, 2026
Article Summary
HOLD- Erasca Inc. (NASDAQ: ERAS) suffered a major stock-market event in August 2026, prompting Kaplan Fox to encourage investors who suffered losses to contact the firm before August 10, 2026.
- The company's stock declined sharply after a major regulatory announcement that raised questions about its ability to successfully commercialize its platform.
- Investors are urged to contact Kaplan Fox as soon as possible to discuss potential recovery options.
- The firm emphasizes that investors should focus on the specific news event rather than the broader company profile.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 0.0% | 25% | 20.0 ptsMinimal (0.0%) - Very weak |
| EPS Growth Next 5Y ? | -15.2% | 25% | 0.0 ptsNegative (-15.2%) - Declining expectations |
| Target Price Upside ? | 18.0% | 20% | 60.0 ptsModerate Upside (18.0%) - Target: $22.55 vs Current: $19.11 |
| Gross Margin % ? | — | 15% | 40.0 ptsNo Gross Margin Data |
| Drawdown from 52-Wk High ? | -21.3% | 15% | 40.0 ptsMild Pullback (-21.3%) - Light entry opportunity |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About ERAS
- Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.
- The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors.
- It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds.
- The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015.
- Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.